. "\u062C\u064A\u0645\u062A\u0648\u0632\u0648\u0645\u0627\u0628 \u0623\u0648\u0632\u0648\u063A\u0627\u0645\u064A\u0633\u064A\u0646 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Gemtuzumab ozogamicin)\u200F\u0647\u0648 \u062C\u0633\u0645 \u0645\u0636\u0627\u062F \u0648\u062D\u064A\u062F \u0627\u0644\u0646\u0633\u064A\u0644\u0629 \u0645\u0631\u062A\u0628\u0637 \u0628\u062F\u0648\u0627\u0621. \u0627\u0633\u062A\u062E\u062F\u0645 \u0644\u0639\u0644\u0627\u062C \u0627\u0628\u064A\u0636\u0627\u0636 \u0627\u0644\u062F\u0645 \u0627\u0644\u0646\u0642\u0648\u064A \u0627\u0644\u062D\u0627\u062F \u0644\u0644\u0641\u062A\u0631\u0629 2000-2010 \u0644\u0643\u0646\u0647 \u0633\u062D\u0628 \u0645\u0646 \u0627\u0644\u0627\u0633\u062A\u062E\u062F\u0627\u0645 \u0641\u064A \u062D\u0632\u064A\u0631\u0627\u0646 2010 \u0628\u0639\u062F \u062A\u0642\u0627\u0631\u064A\u0631 \u062A\u0641\u064A\u062F \u0628\u0627\u0631\u062A\u0641\u0627\u0639 \u0645\u0639\u062F\u0644\u0627\u062A \u0627\u0644\u0648\u0641\u0627\u0629 \u0625\u0636\u0627\u0641\u0629 \u0644\u0639\u062F\u0645 \u0648\u062C\u0648\u062F \u0641\u0627\u0626\u062F\u0629 \u062A\u0636\u0627\u0641 \u0625\u0644\u0649 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0628\u062F\u064A\u0644\u0629 \u0627\u0644\u0623\u062E\u0631\u0649. \u0627\u0644\u062F\u0648\u0627\u0621 \u062E\u0644\u0627\u0644 \u0641\u062A\u0631\u0629 \u062A\u0633\u0648\u064A\u0642\u0647 \u062A\u0639\u0631\u0636 \u0644\u0646\u0642\u062F \u0643\u062B\u064A\u0631 \u0628\u0633\u0628\u0628 \u0623\u0639\u0631\u0627\u0636\u0647 \u0627\u0644\u062C\u0627\u0646\u0628\u064A\u0629 \u0648\u0642\u0644\u0629 \u0645\u0631\u0627\u0642\u0628\u0629 \u0627\u0633\u062A\u062E\u062F\u0627\u0645\u0647. \u0633\u0648\u0642\u062A\u0647 \u0648\u0627\u064A\u062B (\u0627\u0644\u062A\u064A \u0627\u0633\u062A\u062D\u0648\u0630\u062A \u0639\u0644\u064A\u0647\u0627 \u0641\u0627\u064A\u0632\u0631) \u062A\u062D\u062A \u0627\u0633\u0645 \u062A\u062C\u0627\u0631\u064A \u0647\u0648 \u0645\u0627\u064A\u0644\u0648\u062A\u0627\u0631\u063A (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Mylotarg)\u200F\u060C \u0648\u0642\u062F \u0633\u062D\u0628\u062A\u0647 \u0641\u0627\u064A\u0632\u0631 \u0628\u0637\u0644\u0628 \u0645\u0646 \u0625\u062F\u0627\u0631\u0629 \u0627\u0644\u063A\u0630\u0627\u0621 \u0648\u0627\u0644\u062F\u0648\u0627\u0621."@ar . . . . . "220578"^^ . . "D03259" . . "Gentuzumab ozogamicina"@pt . . "changed"@en . . "Gemtuzumab-Ozogamicin (auch Gemtuzumab ozogamicin geschrieben; Handelsname Mylotarg; Hersteller Wyeth) ist ein Immunkonjugat, das aus einem humanisierten, mit einem bakteriellen Toxin verbundenen, monoklonalen Antik\u00F6rper besteht. Der monoklonale Antik\u00F6rper ist gegen das CD33-Antigen gerichtet und wird im Rahmen einer Krebsimmuntherapie zur Behandlung der akuten myeloischen Leuk\u00E4mie (AML) eingesetzt. Seit April 2018 ist er zur Behandlung der CD33 positiven AML in Kombination mit Chemotherapie zugelassen."@de . . "L01"@en . . "Rx-only / Schedule D"@en . . "Rx-only"@en . . "151500"^^ . "\u0413\u0435\u043C\u0442\u0443\u0437\u0443\u043C\u0430\u0431 \u043E\u0437\u043E\u0433\u0430\u043C\u0438\u0446\u0438\u043D"@ru . . . "Gemtuzumab ozogamicin"@en . "Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute myeloid leukemia. The most common grade 3 and higher adverse reactions that occurred during Induction 1 and Intensification 2 in \u2265 5% of people who received gemtuzumab ozogamicin were infection, febrile neutropenia, decreased appetite, hyperglycemia, mucositis, hypoxia, hemorrhage, increased transaminase, diarrhea, nausea, and hypotension."@en . . . . . "Gemtuzumab-Ozogamicin (auch Gemtuzumab ozogamicin geschrieben; Handelsname Mylotarg; Hersteller Wyeth) ist ein Immunkonjugat, das aus einem humanisierten, mit einem bakteriellen Toxin verbundenen, monoklonalen Antik\u00F6rper besteht. Der monoklonale Antik\u00F6rper ist gegen das CD33-Antigen gerichtet und wird im Rahmen einer Krebsimmuntherapie zur Behandlung der akuten myeloischen Leuk\u00E4mie (AML) eingesetzt. Seit April 2018 ist er zur Behandlung der CD33 positiven AML in Kombination mit Chemotherapie zugelassen."@de . . "a618005"@en . . . . "1201506"^^ . . . . . . "8GZG754X6M" . . . "FX02"@en . "\u0413\u0435\u043C\u0442\u0443\u0437\u0443\u043C\u0430\u0431 \u043E\u0437\u043E\u0433\u0430\u043C\u0456\u0446\u0438\u043D (\u0430\u043D\u0433\u043B. Gemtuzumab ozogamicin, \u043B\u0430\u0442. Gemtuzumabum ozogamicin) \u2014 \u0441\u0438\u043D\u0442\u0435\u0442\u0438\u0447\u043D\u0438\u0439 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442, \u044F\u043A\u0438\u0439 \u0454 \u043B\u044E\u0434\u0441\u044C\u043A\u0438\u043C \u043C\u043E\u043D\u043E\u043A\u043B\u043E\u043D\u0430\u043B\u044C\u043D\u0438\u043C \u0430\u043D\u0442\u0438\u0442\u0456\u043B\u043E\u043C \u0434\u043E CD33, \u0442\u0430 \u0454 \u043A\u043E\u043D'\u044E\u0433\u0430\u0442\u043E\u043C \u0430\u043D\u0442\u0438\u0442\u0456\u043B\u0430 \u0437 \u043B\u0456\u043A\u0430\u0440\u0441\u044C\u043A\u0438\u043C \u0437\u0430\u0441\u043E\u0431\u043E\u043C, \u0449\u043E \u0440\u043E\u0437\u0440\u043E\u0431\u043B\u0435\u043D\u0438\u0439 \u0434\u043B\u044F \u043B\u0456\u043A\u0443\u0432\u0430\u043D\u043D\u044F \u0433\u043E\u0441\u0442\u0440\u043E\u0433\u043E \u043C\u0456\u0454\u043B\u043E\u0431\u043B\u0430\u0441\u0442\u043D\u043E\u0433\u043E \u043B\u0435\u0439\u043A\u043E\u0437\u0443, \u044F\u043A\u0438\u0439 \u0437\u0430\u0441\u0442\u043E\u0441\u043E\u0432\u0443\u0454\u0442\u044C\u0441\u044F \u0432\u043D\u0443\u0442\u0440\u0456\u0448\u043D\u044C\u043E\u0432\u0435\u043D\u043D\u043E. \u0413\u0435\u043C\u0442\u0443\u0437\u0443\u043C\u0430\u0431 \u043E\u0437\u043E\u0433\u0430\u043C\u0456\u0446\u0438\u043D \u0440\u043E\u0437\u0440\u043E\u0431\u043B\u044F\u0432\u0441\u044F \u0443 \u0441\u043F\u0456\u0432\u043F\u0440\u0430\u0446\u0456 \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u0439 \u0456 \u0437 1991 \u0440\u043E\u043A\u0443, \u043F\u0456\u0441\u043B\u044F \u0432\u0445\u043E\u0434\u0436\u0435\u043D\u043D\u044F \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u0439 \u0434\u043E \u0441\u043A\u043B\u0430\u0434\u0443 \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u0457 \u00ABPfizer\u00BB \u0441\u0430\u043C\u0435 \u0446\u044F \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u044F \u0437 2009 \u0440\u043E\u043A\u0443 \u0437\u0430\u0439\u043C\u0430\u0454\u0442\u044C\u0441\u044F \u0434\u043E\u0441\u043B\u0456\u0434\u0436\u0435\u043D\u043D\u044F\u043C\u0438 \u0442\u0430 \u043C\u0430\u0440\u043A\u0435\u0442\u0438\u043D\u0433\u043E\u043C \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0443."@uk . . . . . "changed"@en . "8"^^ . "\u30B2\u30E0\u30C4\u30BA\u30DE\u30D6 \u30AA\u30BE\u30AC\u30DE\u30A4\u30B7\u30F3\uFF08Gemtuzumab ozogamicin\uFF09\u306F\u6025\u6027\u9AA8\u9AC4\u6027\u767D\u8840\u75C5\uFF08Acute Myelogenous Leukemia\uFF1AAML\uFF09\u306E\u6CBB\u7642\u306B\u7528\u3044\u3089\u308C\u308B\u6297\u4F53\u85AC\u7269\u8907\u5408\u4F53\uFF08Antibody-drug conjugate\u3001ADC\uFF09\u306E\u4E00\u3064\u3067\u3042\u308B\u3002\u306B\u5BFE\u3059\u308B\u30D2\u30C8\u5316\u30E2\u30CE\u30AF\u30ED\u30FC\u30CA\u30EB\u6297\u4F53\uFF08\u30B2\u30E0\u30C4\u30BA\u30DE\u30D6\uFF09\u90E8\u5206\u3068\u3001\u7D30\u80DE\u6BD2\u6027\u3092\u6709\u3059\u308B\u30AB\u30EA\u30B1\u30A2\u30DF\u30B7\u30F3\u7CFB\u306E\u30AA\u30BE\u30AC\u30DE\u30A4\u30B7\u30F3\u90E8\u5206\u304B\u3089\u6210\u308B\u3002\u5546\u54C1\u540D\u30DE\u30A4\u30ED\u30BF\u30FC\u30B0\u3002\u7C73\u56FD\u3067\u306F2000\u5E74\u304B\u30892010\u5E74\u307E\u3067\u8CA9\u58F2\u3055\u308C\u3066\u3044\u305F\u304C\u3001\u30C0\u30A6\u30CE\u30EB\u30D3\u30B7\u30F3\u30FB\u30B7\u30BF\u30E9\u30D3\u30F3\u4F75\u7528\u7642\u6CD5\u3078\u306E\u4E0A\u4E57\u305B\u306A\u3089\u3073\u306B\u30B7\u30BF\u30E9\u30D3\u30F3\u5927\u91CF\u6295\u4E0E\u3078\u306E\u4E0A\u4E57\u305B\u3067\u6709\u52B9\u6027\u304C\u898B\u3089\u308C\u305A\u3001\u6B7B\u4EA1\u4F8B\u304C\u5897\u52A0\u3057\u305F\u3068\u3057\u3066\u627F\u8A8D\u53D6\u4E0B\u3052\u3068\u306A\u3063\u305F\u3002\u65E5\u672C\u3067\u306F2005\u5E745\u6708\u306B\u627F\u8A8D\u3055\u308C\u3001\u6DFB\u4ED8\u6587\u66F8\u306E\u8B66\u544A\u6B04\u3067\u3001\u4ED6\u306E\u6297\u60AA\u6027\u816B\u760D\u5264\u3068\u4F75\u7528\u3057\u306A\u3044\u3053\u3068\u3068\u3055\u308C\u3066\u304A\u308A\u8CA9\u58F2\u306F\u7D99\u7D9A\u3055\u308C\u3066\u3044\u308B\u3002"@ja . "\u0413\u0435\u043C\u0442\u0443\u0437\u0443\u043C\u0430\u0431 \u043E\u0437\u043E\u0433\u0430\u043C\u0456\u0446\u0438\u043D"@uk . . . . "Gemtuzumab ozogamycyny \u2014 lek cytostatyczny, stosowany dawniej w leczeniu ostrej bia\u0142aczki szpikowej u pacjent\u00F3w z dodatnimi wynikami bada\u0144 w kierunku receptor\u00F3w CD33, u kt\u00F3rych wyst\u0105pi\u0142 nawr\u00F3t choroby po wcze\u015Bniejszym kursie leczenia oraz kt\u00F3rzy nie kwalifikowali si\u0119 do innych typ\u00F3w intensywnej chemioterapii. W dniu 18 pa\u017Adziernika 2000 zosta\u0142 oznaczony jako sierocy produkt leczniczy do leczenia ostrej bia\u0142aczki szpikowej."@pl . . "Le gemtuzumab ozogamicine est un anticorps monoclonal dirig\u00E9 contre le CD33 et coupl\u00E9 \u00E0 l'ozogamicine, une mol\u00E9cule cytotoxique. Ce m\u00E9dicament est utilis\u00E9 dans le traitement des leuc\u00E9mies aigu\u00EBs my\u00E9lo\u00EFdes CD33+."@fr . . . "\u30B2\u30E0\u30C4\u30BA\u30DE\u30D6 \u30AA\u30BE\u30AC\u30DE\u30A4\u30B7\u30F3\uFF08Gemtuzumab ozogamicin\uFF09\u306F\u6025\u6027\u9AA8\u9AC4\u6027\u767D\u8840\u75C5\uFF08Acute Myelogenous Leukemia\uFF1AAML\uFF09\u306E\u6CBB\u7642\u306B\u7528\u3044\u3089\u308C\u308B\u6297\u4F53\u85AC\u7269\u8907\u5408\u4F53\uFF08Antibody-drug conjugate\u3001ADC\uFF09\u306E\u4E00\u3064\u3067\u3042\u308B\u3002\u306B\u5BFE\u3059\u308B\u30D2\u30C8\u5316\u30E2\u30CE\u30AF\u30ED\u30FC\u30CA\u30EB\u6297\u4F53\uFF08\u30B2\u30E0\u30C4\u30BA\u30DE\u30D6\uFF09\u90E8\u5206\u3068\u3001\u7D30\u80DE\u6BD2\u6027\u3092\u6709\u3059\u308B\u30AB\u30EA\u30B1\u30A2\u30DF\u30B7\u30F3\u7CFB\u306E\u30AA\u30BE\u30AC\u30DE\u30A4\u30B7\u30F3\u90E8\u5206\u304B\u3089\u6210\u308B\u3002\u5546\u54C1\u540D\u30DE\u30A4\u30ED\u30BF\u30FC\u30B0\u3002\u7C73\u56FD\u3067\u306F2000\u5E74\u304B\u30892010\u5E74\u307E\u3067\u8CA9\u58F2\u3055\u308C\u3066\u3044\u305F\u304C\u3001\u30C0\u30A6\u30CE\u30EB\u30D3\u30B7\u30F3\u30FB\u30B7\u30BF\u30E9\u30D3\u30F3\u4F75\u7528\u7642\u6CD5\u3078\u306E\u4E0A\u4E57\u305B\u306A\u3089\u3073\u306B\u30B7\u30BF\u30E9\u30D3\u30F3\u5927\u91CF\u6295\u4E0E\u3078\u306E\u4E0A\u4E57\u305B\u3067\u6709\u52B9\u6027\u304C\u898B\u3089\u308C\u305A\u3001\u6B7B\u4EA1\u4F8B\u304C\u5897\u52A0\u3057\u305F\u3068\u3057\u3066\u627F\u8A8D\u53D6\u4E0B\u3052\u3068\u306A\u3063\u305F\u3002\u65E5\u672C\u3067\u306F2005\u5E745\u6708\u306B\u627F\u8A8D\u3055\u308C\u3001\u6DFB\u4ED8\u6587\u66F8\u306E\u8B66\u544A\u6B04\u3067\u3001\u4ED6\u306E\u6297\u60AA\u6027\u816B\u760D\u5264\u3068\u4F75\u7528\u3057\u306A\u3044\u3053\u3068\u3068\u3055\u308C\u3066\u304A\u308A\u8CA9\u58F2\u306F\u7D99\u7D9A\u3055\u308C\u3066\u3044\u308B\u3002"@ja . . . "Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute myeloid leukemia. The most common grade 3 and higher adverse reactions that occurred during Induction 1 and Intensification 2 in \u2265 5% of people who received gemtuzumab ozogamicin were infection, febrile neutropenia, decreased appetite, hyperglycemia, mucositis, hypoxia, hemorrhage, increased transaminase, diarrhea, nausea, and hypotension."@en . . . "1116912997"^^ . . "mab"@en . "S4"@en . . . "1201506" . "none"@en . "POM"@en . . . "\u0413\u0435\u043C\u0442\u0443\u0437\u0443\u043C\u0430\u0431 \u043E\u0437\u043E\u0433\u0430\u043C\u0456\u0446\u0438\u043D (\u0430\u043D\u0433\u043B. Gemtuzumab ozogamicin, \u043B\u0430\u0442. Gemtuzumabum ozogamicin) \u2014 \u0441\u0438\u043D\u0442\u0435\u0442\u0438\u0447\u043D\u0438\u0439 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442, \u044F\u043A\u0438\u0439 \u0454 \u043B\u044E\u0434\u0441\u044C\u043A\u0438\u043C \u043C\u043E\u043D\u043E\u043A\u043B\u043E\u043D\u0430\u043B\u044C\u043D\u0438\u043C \u0430\u043D\u0442\u0438\u0442\u0456\u043B\u043E\u043C \u0434\u043E CD33, \u0442\u0430 \u0454 \u043A\u043E\u043D'\u044E\u0433\u0430\u0442\u043E\u043C \u0430\u043D\u0442\u0438\u0442\u0456\u043B\u0430 \u0437 \u043B\u0456\u043A\u0430\u0440\u0441\u044C\u043A\u0438\u043C \u0437\u0430\u0441\u043E\u0431\u043E\u043C, \u0449\u043E \u0440\u043E\u0437\u0440\u043E\u0431\u043B\u0435\u043D\u0438\u0439 \u0434\u043B\u044F \u043B\u0456\u043A\u0443\u0432\u0430\u043D\u043D\u044F \u0433\u043E\u0441\u0442\u0440\u043E\u0433\u043E \u043C\u0456\u0454\u043B\u043E\u0431\u043B\u0430\u0441\u0442\u043D\u043E\u0433\u043E \u043B\u0435\u0439\u043A\u043E\u0437\u0443, \u044F\u043A\u0438\u0439 \u0437\u0430\u0441\u0442\u043E\u0441\u043E\u0432\u0443\u0454\u0442\u044C\u0441\u044F \u0432\u043D\u0443\u0442\u0440\u0456\u0448\u043D\u044C\u043E\u0432\u0435\u043D\u043D\u043E. \u0413\u0435\u043C\u0442\u0443\u0437\u0443\u043C\u0430\u0431 \u043E\u0437\u043E\u0433\u0430\u043C\u0456\u0446\u0438\u043D \u0440\u043E\u0437\u0440\u043E\u0431\u043B\u044F\u0432\u0441\u044F \u0443 \u0441\u043F\u0456\u0432\u043F\u0440\u0430\u0446\u0456 \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u0439 \u0456 \u0437 1991 \u0440\u043E\u043A\u0443, \u043F\u0456\u0441\u043B\u044F \u0432\u0445\u043E\u0434\u0436\u0435\u043D\u043D\u044F \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u0439 \u0434\u043E \u0441\u043A\u043B\u0430\u0434\u0443 \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u0457 \u00ABPfizer\u00BB \u0441\u0430\u043C\u0435 \u0446\u044F \u043A\u043E\u043C\u043F\u0430\u043D\u0456\u044F \u0437 2009 \u0440\u043E\u043A\u0443 \u0437\u0430\u0439\u043C\u0430\u0454\u0442\u044C\u0441\u044F \u0434\u043E\u0441\u043B\u0456\u0434\u0436\u0435\u043D\u043D\u044F\u043C\u0438 \u0442\u0430 \u043C\u0430\u0440\u043A\u0435\u0442\u0438\u043D\u0433\u043E\u043C \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0443."@uk . "Gentuzumab ozogamicina, vendido sob o nome comercial Mylotarg, \u00E9 um f\u00E1rmaco utilizado pela medicina como antineopl\u00E1sico."@pt . . . . . . . . . . "476992617"^^ . . . . . . . . . . . . . "a618005" . . "\u062C\u064A\u0645\u062A\u0648\u0632\u0648\u0645\u0627\u0628 \u0623\u0648\u0632\u0648\u063A\u0627\u0645\u064A\u0633\u064A\u0646"@ar . "2921579"^^ . . . "\u30B2\u30E0\u30C4\u30BA\u30DE\u30D6 \u30AA\u30BE\u30AC\u30DE\u30A4\u30B7\u30F3"@ja . . "\u0413\u0435\u043C\u0442\u0443\u0437\u0443\u043C\u0430\u0431 \u043E\u0437\u043E\u0433\u0430\u043C\u0438\u0446\u0438\u043D \u2014 \u043F\u0435\u0440\u0432\u044B\u0439 \u043A\u043E\u043D\u044A\u044E\u0433\u0430\u0442 \u0430\u043D\u0442\u0438\u0442\u0435\u043B\u043E-\u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442 \u0434\u043B\u044F \u043B\u0435\u0447\u0435\u043D\u0438\u044F \u043E\u0441\u0442\u0440\u043E\u0433\u043E \u043C\u0438\u0435\u043B\u043E\u0438\u0434\u043D\u043E\u0433\u043E \u043B\u0435\u0439\u043A\u043E\u0437\u0430."@ru . . . . "Gemtuzumab ozogamycyny"@pl . "Gemtuzumab_ozogamicin"@en . . . . . . . . . "Il gemtuzumab ozogamicin o Mylotarg nome commerciale, veniva prodotto dalla Wyeth poi Pfizer. Esso \u00E8 anticorpo monoclonale immuno-coniugato costituito da una parteumanizzata associata a una .L'anticorpo monoclonale agisce contro l'antigene CD33 e veniva utilizzato nella immunoterapia di forme di tumore.Il gemtuzumab ozogamicin veniva utilizzato nel trattamento della Leucemia mieloide acuta(AML). Il Mylotarg \u00E8 stato tolto dal mercato nel 2010, mentre nel 2008 una domanda registrativa veniva respinte dalla EMEA."@it . "Gemtuzumab ozogamycyny \u2014 lek cytostatyczny, stosowany dawniej w leczeniu ostrej bia\u0142aczki szpikowej u pacjent\u00F3w z dodatnimi wynikami bada\u0144 w kierunku receptor\u00F3w CD33, u kt\u00F3rych wyst\u0105pi\u0142 nawr\u00F3t choroby po wcze\u015Bniejszym kursie leczenia oraz kt\u00F3rzy nie kwalifikowali si\u0119 do innych typ\u00F3w intensywnej chemioterapii. W dniu 18 pa\u017Adziernika 2000 zosta\u0142 oznaczony jako sierocy produkt leczniczy do leczenia ostrej bia\u0142aczki szpikowej."@pl . . . . . . . . "Mylotarg"@en . . "\u0413\u0435\u043C\u0442\u0443\u0437\u0443\u043C\u0430\u0431 \u043E\u0437\u043E\u0433\u0430\u043C\u0438\u0446\u0438\u043D \u2014 \u043F\u0435\u0440\u0432\u044B\u0439 \u043A\u043E\u043D\u044A\u044E\u0433\u0430\u0442 \u0430\u043D\u0442\u0438\u0442\u0435\u043B\u043E-\u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442 \u0434\u043B\u044F \u043B\u0435\u0447\u0435\u043D\u0438\u044F \u043E\u0441\u0442\u0440\u043E\u0433\u043E \u043C\u0438\u0435\u043B\u043E\u0438\u0434\u043D\u043E\u0433\u043E \u043B\u0435\u0439\u043A\u043E\u0437\u0430."@ru . . "zu/o"@en . "Il gemtuzumab ozogamicin o Mylotarg nome commerciale, veniva prodotto dalla Wyeth poi Pfizer. Esso \u00E8 anticorpo monoclonale immuno-coniugato costituito da una parteumanizzata associata a una .L'anticorpo monoclonale agisce contro l'antigene CD33 e veniva utilizzato nella immunoterapia di forme di tumore.Il gemtuzumab ozogamicin veniva utilizzato nel trattamento della Leucemia mieloide acuta(AML). Il Mylotarg \u00E8 stato tolto dal mercato nel 2010, mentre nel 2008 una domanda registrativa veniva respinte dalla EMEA."@it . . . "Gemtuzumab-Ozogamicin"@de . "DB00056" . "Gemtuzumab ozogamicin"@it . . . . . . . . "Le gemtuzumab ozogamicine est un anticorps monoclonal dirig\u00E9 contre le CD33 et coupl\u00E9 \u00E0 l'ozogamicine, une mol\u00E9cule cytotoxique. Ce m\u00E9dicament est utilis\u00E9 dans le traitement des leuc\u00E9mies aigu\u00EBs my\u00E9lo\u00EFdes CD33+."@fr . "Gemtuzumab ozogamicine"@fr . . "mab"@en . "Rx-only"@en . . . "15618"^^ . . "D"@en . "DB00056"@en . "Mylotarg"@en . "\u062C\u064A\u0645\u062A\u0648\u0632\u0648\u0645\u0627\u0628 \u0623\u0648\u0632\u0648\u063A\u0627\u0645\u064A\u0633\u064A\u0646 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Gemtuzumab ozogamicin)\u200F\u0647\u0648 \u062C\u0633\u0645 \u0645\u0636\u0627\u062F \u0648\u062D\u064A\u062F \u0627\u0644\u0646\u0633\u064A\u0644\u0629 \u0645\u0631\u062A\u0628\u0637 \u0628\u062F\u0648\u0627\u0621. \u0627\u0633\u062A\u062E\u062F\u0645 \u0644\u0639\u0644\u0627\u062C \u0627\u0628\u064A\u0636\u0627\u0636 \u0627\u0644\u062F\u0645 \u0627\u0644\u0646\u0642\u0648\u064A \u0627\u0644\u062D\u0627\u062F \u0644\u0644\u0641\u062A\u0631\u0629 2000-2010 \u0644\u0643\u0646\u0647 \u0633\u062D\u0628 \u0645\u0646 \u0627\u0644\u0627\u0633\u062A\u062E\u062F\u0627\u0645 \u0641\u064A \u062D\u0632\u064A\u0631\u0627\u0646 2010 \u0628\u0639\u062F \u062A\u0642\u0627\u0631\u064A\u0631 \u062A\u0641\u064A\u062F \u0628\u0627\u0631\u062A\u0641\u0627\u0639 \u0645\u0639\u062F\u0644\u0627\u062A \u0627\u0644\u0648\u0641\u0627\u0629 \u0625\u0636\u0627\u0641\u0629 \u0644\u0639\u062F\u0645 \u0648\u062C\u0648\u062F \u0641\u0627\u0626\u062F\u0629 \u062A\u0636\u0627\u0641 \u0625\u0644\u0649 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0628\u062F\u064A\u0644\u0629 \u0627\u0644\u0623\u062E\u0631\u0649. \u0627\u0644\u062F\u0648\u0627\u0621 \u062E\u0644\u0627\u0644 \u0641\u062A\u0631\u0629 \u062A\u0633\u0648\u064A\u0642\u0647 \u062A\u0639\u0631\u0636 \u0644\u0646\u0642\u062F \u0643\u062B\u064A\u0631 \u0628\u0633\u0628\u0628 \u0623\u0639\u0631\u0627\u0636\u0647 \u0627\u0644\u062C\u0627\u0646\u0628\u064A\u0629 \u0648\u0642\u0644\u0629 \u0645\u0631\u0627\u0642\u0628\u0629 \u0627\u0633\u062A\u062E\u062F\u0627\u0645\u0647. \u0633\u0648\u0642\u062A\u0647 \u0648\u0627\u064A\u062B (\u0627\u0644\u062A\u064A \u0627\u0633\u062A\u062D\u0648\u0630\u062A \u0639\u0644\u064A\u0647\u0627 \u0641\u0627\u064A\u0632\u0631) \u062A\u062D\u062A \u0627\u0633\u0645 \u062A\u062C\u0627\u0631\u064A \u0647\u0648 \u0645\u0627\u064A\u0644\u0648\u062A\u0627\u0631\u063A (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Mylotarg)\u200F\u060C \u0648\u0642\u062F \u0633\u062D\u0628\u062A\u0647 \u0641\u0627\u064A\u0632\u0631 \u0628\u0637\u0644\u0628 \u0645\u0646 \u0625\u062F\u0627\u0631\u0629 \u0627\u0644\u063A\u0630\u0627\u0621 \u0648\u0627\u0644\u062F\u0648\u0627\u0621."@ar . . . . . . "D03259"@en . "Gentuzumab ozogamicina, vendido sob o nome comercial Mylotarg, \u00E9 um f\u00E1rmaco utilizado pela medicina como antineopl\u00E1sico."@pt . . . "220578-59-6" .